Abbvie Inc.

Dennis Andress

James C Stolzenbach

Blas Coll Crespo

John J Brennan

The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.

Growing community of inventors

Chicago, IL, United States of America

Dennis Andress